ライフサイエンスコーパス: hepatorenal

1 l cardiac defects, abnormal left-right axis, hepatorenal and pancreatic cysts, and embryonic lethalit

2 PAS is more effective than OCT in reducing hepatorenal cystogenesis in rodent models; therefore, it

3 h of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS

4 with autosomal dominant PKD (ADPKD); and (2) hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS

5 denosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis.

6 es and hepatic hydrothorax, and treatment of hepatorenal failure and hepatopulmonary syndrome.

7 Fatal hepatorenal failure may occur after the use of hydrazine

8 te lethality associated with signs of severe hepatorenal failure when mice are fed with a diet that e

9 onephritis, and 1 with acetaminophen-induced hepatorenal failure).

10 hosphatemia reflects a derangement of normal hepatorenal messaging and is the result of a disruption

11 her lipid indexes or markers associated with hepatorenal or cardiovascular function.

12 In conclusion, Pkd2ws25/- mice exhibit hepatorenal pathology resembling human autosomal dominan

13 ogy in the orpk mutant mouse that displays a hepatorenal pathology that is similar to that seen in hu

14 Our results provide further support for hepatorenal reciprocity and may explain at least in part

15 ther observations have led to the concept of hepatorenal reciprocity.

16 on, renal blood flow declines because of the hepatorenal reflex, and is then maintained by the vasoac

17 A higher proportion of patients on NSBBs had hepatorenal syndrome (24% vs 11% in those not taking NSB

18 a (68.6 %), acute tubular necrosis (25.7 %), hepatorenal syndrome (5.7 %), respectively.

19 re sepsis (27% versus 9%, P = 0.003), type-1 hepatorenal syndrome (HRS) (16% versus 3%, P = 0.002), a

20 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemor

21 Type-1 hepatorenal syndrome (HRS) is a common complication of b

22 nd albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver tr

23 Hepatorenal syndrome (HRS) type 1 is a progressive funct

24 Fourteen patients with LVDD developed hepatorenal syndrome (HRS) type 1 on follow-up.

25 e prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerena

26 Hepatorenal syndrome (HRS), a serious complication of ci

27 edict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality.

28 s including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

29 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

30 In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used e

31 nally may be done for the renal diagnosis of hepatorenal syndrome (HRS).

32 mia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS).

33 Type 2 hepatorenal syndrome (HRS2) is a functional renal impair

34 ions, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT =

35 reversal of hepatorenal syndrome, relapse of hepatorenal syndrome after initial reversal, and adverse

36 ised, time of hospitalization, and risks for hepatorenal syndrome and acute kidney injury.

37 with secondary end points of development of hepatorenal syndrome and response to therapy based on th

38 re two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

39 The cumulative incidence of hepatorenal syndrome at 6 months was not significantly d

40 Otherwise, hepatorenal syndrome carries a high mortality.

41 Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstri

42 n methods for the treatment or prevention of hepatorenal syndrome except to maintain adequate hemodyn

43 adrenaline-treated patients with reversal of hepatorenal syndrome had recurrence on discontinuation o

44 The development of hepatorenal syndrome in liver cirrhosis leads to an incr

45 ients with acute liver failure (ALF) in whom hepatorenal syndrome is common.

46 avenous albumin therapy for the treatment of hepatorenal syndrome is ongoing with a growing body of r

47 Hepatorenal syndrome may improve by increasing renal blo

48 The hepatorenal syndrome represents the result of extreme va

49 The hepatorenal syndrome represents the result of extreme va

50 Hyponatremia and the hepatorenal syndrome result from water retention and ren

51 A meta-analysis was performed of hepatorenal syndrome reversal and survival in relation t

52 The pooled percentage of patients achieving hepatorenal syndrome reversal was 49.5% (95% confidence

53 significant increase of similar magnitude in hepatorenal syndrome reversal was also observed (odds ra

54 Neither survival nor hepatorenal syndrome reversal was significantly affected

55 CLKT patients with hepatorenal syndrome showed significantly higher patient

56 ars) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of activ

57 Clinical studies of type 1 hepatorenal syndrome treatment with albumin and vasocons

58 Hepatorenal syndrome type 1 (HRS-1) in patients with cir

59 o further decompensation (variceal bleeding, hepatorenal syndrome) and improves survival.

60 included other specific liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliar

61 nd reversible causes of renal failure (i.e., hepatorenal syndrome), whereas combined liver and kidney

62 Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially rever

63 t study using this shunt in the treatment of hepatorenal syndrome, a trial of antibiotic prophylaxis

64 No patient developed hepatorenal syndrome, and 1-year survival of 67% was bet

65 ores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.

66 ch as variceal bleeding, encephalopathy, and hepatorenal syndrome, and sociodemographic factors, such

67 sin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use i

68 tudied to improve outcomes for patients with hepatorenal syndrome, but trials have reported variable

69 rrhotic patients with RF, in particular with hepatorenal syndrome, CLKT is preferable to LTA because

70 sociated with time-dependent change in eGFR, hepatorenal syndrome, dialysis requirement, hepatitis C,

71 gth of stay was associated with eGFR at OLT, hepatorenal syndrome, dialysis requirement, model for en

72 h as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

73 In patients with hepatorenal syndrome, hemodialysis can be used as a brid

74 The percentages of patients who developed hepatorenal syndrome, hepatic encephalopathy, or sepsis

75 rmed in case of different conditions such as hepatorenal syndrome, hepatichydrothorax, portal vein th

76 Hepatorenal syndrome, hepatocellular carcinoma, variceal

77 disposes the patient to variceal hemorrhage, hepatorenal syndrome, hepatopulmonary syndrome, and unco

78 evels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for

79 Hepatorenal syndrome, HRS, is a diagnosis of exclusion.

80 alopathy, ascites, hepatocellular carcinoma, hepatorenal syndrome, or bleeding caused by portal hyper

81 ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or fulminant hepatic failure.

82 Secondary outcomes were reversal of hepatorenal syndrome, relapse of hepatorenal syndrome af

83 sode and secondary prophylaxis), ascites and hepatorenal syndrome, spontaneous bacterial peritonitis

84 cations (hyponatremia, hepatic hydrothorax), hepatorenal syndrome, spontaneous bacterial peritonitis,

85 ), portal hypertensive gastropathy, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis,

86 ect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the gro

87 de (OR 26.25, 95% CI 3.07-224.21) to reverse hepatorenal syndrome, with low-quality evidence supporti

88 ctiveness and safety in patients with type 1 hepatorenal syndrome.

89 rolled trials done in 739 adults with type 1 hepatorenal syndrome.

90 , ascites, encephalopathy, coagulopathy, and hepatorenal syndrome.

91 plus octreotide with albumin for reversal of hepatorenal syndrome.

92 ompared with placebo in patients with type 1 hepatorenal syndrome.

93 , bacterial infection, and/or development of hepatorenal syndrome.

94 albumin and survival in patients with type 1 hepatorenal syndrome.

95 is useful in the management of patients with hepatorenal syndrome.

96 ut also heart failure in the pathogenesis of hepatorenal syndrome.

97 rome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

98 o the prevention and effective treatment for hepatorenal syndrome.

99 ompared with placebo in patients with type 1 hepatorenal syndrome.

100 ewer patients receiving colchicine developed hepatorenal syndrome.

101 f different management strategies for type 1 hepatorenal syndrome.

102 serum creatinine and are more likely to have hepatorenal syndrome.

103 There are two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and ty

104 Search terms included: hepatorenal syndrome; albumin; vasoconstrictor; terlipre

105 s of IAH may also be seen in cardiorenal and hepatorenal syndromes.

106 and progressive liver dysfunction, underwent hepatorenal transplantation.

107 including succinylacetone (SA), a marker for hepatorenal tyrosinemia.